Wellington Management Group LLP Purchases 27,531 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Wellington Management Group LLP grew its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 43.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,529 shares of the company's stock after acquiring an additional 27,531 shares during the quarter. Wellington Management Group LLP owned 0.15% of Mineralys Therapeutics worth $1,127,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Mineralys Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock worth $2,645,000 after acquiring an additional 1,307 shares during the period. Northern Trust Corp lifted its position in shares of Mineralys Therapeutics by 0.7% in the 4th quarter. Northern Trust Corp now owns 246,113 shares of the company's stock worth $3,030,000 after acquiring an additional 1,688 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Mineralys Therapeutics by 2.7% during the 4th quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company's stock worth $804,000 after buying an additional 1,711 shares during the period. Wells Fargo & Company MN lifted its position in shares of Mineralys Therapeutics by 19.1% during the 4th quarter. Wells Fargo & Company MN now owns 23,714 shares of the company's stock worth $292,000 after buying an additional 3,802 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in shares of Mineralys Therapeutics during the 4th quarter worth approximately $48,000. Institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock traded up $0.50 during midday trading on Friday, hitting $16.12. 394,653 shares of the company were exchanged, compared to its average volume of 502,064. The firm has a 50 day simple moving average of $14.48 and a 200-day simple moving average of $12.75. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $18.38. The firm has a market cap of $1.05 billion, a P/E ratio of -4.43 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. acquired 1,296,296 shares of the business's stock in a transaction on Thursday, March 13th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $17,499,996.00. Following the transaction, the director now owns 4,280,051 shares in the company, valued at $57,780,688.50. This trade represents a 43.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jon Congleton sold 15,319 shares of Mineralys Therapeutics stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.19, for a total value of $186,738.61. Following the completion of the transaction, the chief executive officer now owns 862,289 shares of the company's stock, valued at approximately $10,511,302.91. The trade was a 1.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,579 shares of company stock worth $1,534,353. 25.56% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently commented on MLYS. Guggenheim set a $48.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th. The Goldman Sachs Group cut their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Finally, Wall Street Zen upgraded Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.